REG - Genflow Biosciences - Appointment and Internal Restructure

Genflow BiosciencesAnnouncement

11/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230511:nRSK9662Ya&default-theme=true

RNS Number : 9662Y  Genflow Biosciences PLC  11 May 2023

11 May 2023

 

Genflow Biosciences Plc

 

("Genflow" or "the Company")

 

Appointment and Internal Restructure

 

 

In light of the ongoing progress being achieved by Genflow, the Board of
Directors has proactively decided to restructure both itself and the Company's
Scientific Advisory Board ("SAB"). This step has been taken to align with the
Company's current objectives and priorities in the US, including the OTCQB
application previously announced, as outlined below:

 

(a)  Tamara Joseph, the Company's US-based Non-Executive Director, has been
promoted to Chairperson of the Board. Her experience in financing, coupled
with her familiarity with the US public markets, will play a crucial role
going forward.

Tamara has an impressive track record in public and private financings, having
supported Nasdaq financings in excess of $800m. Her expertise in the field of
finance is further strengthened by her academic credentials, which include a
JD from the University of Michigan Law School and LLM degrees from the College
of Europe in Belgium and the University of Paris.

Having served as an adviser to the boards of five US publicly traded biotechs,
Tamara has demonstrated a strong ability to lead companies. Her promotion is a
recognition of her expertise and strengthens the Company's links with the US
market.

Yassine Bendiabdallah, will remain a key member of the Board and will continue
to act as a Non-Executive Director.

(b)  Vera Gorbunova PhD, has been promoted to Chairperson of the SAB. Dr
Gorbunova is an endowed Professor of Biology at the University of Rochester,
New York, and Co-Director of the Rochester Ageing Research Center, where her
research focuses on the mechanisms of longevity and genome stability, as well
as studies on exceptionally long-lived mammals.

Throughout her career, Dr. Gorbunova has received numerous awards for her
work, including from the Ellison Medical Foundation, the Glenn Foundation, the
American Federation for Ageing Research, and the National Institutes of
Health. Her research has also been recognized with the Cozzarelli Prize from
PNAS, the prize for research on ageing from ADPS/Alianz (France), the Prince
Hitachi Prize in Comparative Oncology (Japan), and the Davey Prize from Wilmot
Cancer Center.

As Chairperson of the SAB, Dr. Gorbunova's outstanding contributions to the
field of longevity and her invaluable insights in this sector will be
instrumental in guiding the Company's scientific research. This appointment is
a testament to her expertise and achievements in the field.

Dr Eric Verdin will remain a key member of the SAB.

(c)   Professor Dr Sven Francque is joining the SAB.  Professor Francque is
a renowned expert in the field of nonalcoholic fatty liver disease (NAFLD) and
its advanced form, nonalcoholic steatohepatitis (NASH).

He has a long-standing interest and expertise in NAFLD and NASH, with research
focusing on the vascular changes in steatosis and their contribution to
disease progression.  Genflow stands to gain significant value from Professor
Francque's extensive knowledge of NASH, particularly in identifying new
targets and potential therapies for the disease.

Moreover, Professor Francque's expertise in clinical research and clinical
trial design will be invaluable in the development of clinical trial programs
for the Company's novel therapeutics. His membership on the SAB will play a
vital role in shaping and broadening the Company's strategy and direction, and
his vast experience will be integral to achieving the Company's goal of
improving the lives of patients with NAFLD and NASH.

 

 

Yassine Bendiabdallah, Director, commented:  "We remain dedicated to adapting
and evolving in the ever-changing longevity space. Our collective and
individual agility gives us a significant advantage over larger competitors
and allows us to remain at the forefront of this dynamic industry.

 

I am incredibly proud of the strong team we have in place, and it's an honour
to work alongside such esteemed leaders in this field. Our commitment to
innovation and our ability to navigate the dynamic landscape of the longevity
sector is central to our continued success."

 

The information communicated in this announcement is inside information for
the purposes of Article 7 of Regulation 596/2014.

 

 For further information please contact:

 

 Genflow Biosciences Plc
 Dr Eric Leire             +32 477 495 881

 Chief Executive Officer

 Clear Capital Markets
 Corporate Broker          +44 203 869 6080

 Andrew Blaylock

 

About Genflow Biosciences

 

Genflow is a UK-based biotechnology company established in 2020. The Company
is developing gene therapies designed to target the aging process and to
reduce and delay the incidence of age-related diseases. This will be done
through novel therapeutics targeting aging in humans by using adeno-associated
virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene
variant that is found in centenarians into cells.

 

Its mission is to increase our understanding of the factors that control and
impact lifespan. Genflow researches, develops, and commercialises therapeutic
solutions to lengthen health span, the amount of time we live in good health,
creating biological interventions that enable longer and healthier lives.
Genflow is dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging, Genflow
can contribute to a decrease in healthcare costs and lessen the emotional and
societal burden that comes with an aging population.

 

To learn more visit www.genflowbio.com (http://www.genflowbio.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBBLFFXELBBBV